Review
Oncology
Miao Liu, Siyao Liu, Liu Yang, Shu Wang
Summary: This study compared the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and solvent-based taxanes (sb-taxanes) as neoadjuvant therapy in breast cancer treatment, with nab-paclitaxel showing improved pathological complete response rate and event-free survival compared to sb-taxanes.
Article
Oncology
Yimeng Chen, Baoshi Bao, Yao Lv, Decong Sun, Li Zhang, Jiandong Wang, Weihong Zhao
Summary: This study retrospectively evaluated the efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-PTX) and docetaxel (DOC) as neoadjuvant therapy in breast cancer patients. The results showed a higher pathologic complete response rate in the nPBC group compared to the DBC group, indicating potential benefits of nab-PTX-based chemotherapy in early breast cancer treatment.
INVESTIGATIONAL NEW DRUGS
(2021)
Article
Oncology
Jung Sun Kim, Koung Jin Suh, Dae-Won Lee, Go-Un Woo, Miso Kim, Se Hyun Kim, Han Suk Ryu, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, So Yeon Park, In Ae Park, Jee Hyun Kim, Seock-Ah Im
Summary: This study aimed to assess the real-world efficacy of nab-paclitaxel in metastatic breast cancer patients. The results showed that nab-paclitaxel is a reasonable treatment option for heavily pre-treated and/or taxane-exposed patients with metastatic breast cancer.
CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Yizhao Xie, Chengcheng Gong, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Yannan Zhao, Yi Li, Shihui Hu, Biyun Wang, Xichun Hu
Summary: This phase II trial demonstrated satisfactory efficacy and safety of nab-paclitaxel in metastatic breast cancer patients with visceral metastases, with better treatment outcome for patients in first line therapy. Further alternatives may be required for patients with premenopausal status or brain metastasis. The study also showed the efficacy and safety of 125 mg/m2 nab-paclitaxel among Asian patients.
Review
Oncology
Haili Lu, Siluo Zha, Wei Zhang, Qiang Wang, Daozhen Jiang, Xinyun Xu, Xiangmin Zheng, Ming Qiu, Chengxiang Shan
Summary: Nab-paclitaxel mono-chemotherapy shows considerable benefits in the treatment of MBC with manageable harm. Further studies are needed to evaluate the roles of dosage, schedule, and other factors in nab-paclitaxel chemotherapy.
Article
Oncology
Hanwen Wang, Huilin Ma, Richard J. Sove, Leisha A. Emens, Aleksander S. Popel
Summary: This study introduces a modular quantitative systems pharmacology (QSP) platform for predicting immunotherapy efficacy and identifying predictive biomarkers. Virtual clinical trials were conducted using a virtual patient cohort generated by the model, with retrospective analysis and model validation based on clinical trial data.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Biotechnology & Applied Microbiology
Yan Li, Xiang Chen, Qiannan Zhu, Rui Chen, Lu Xu, Shuo Li, Xiaoqing Shi, Haiping Xu, Yinggang Xu, Weiwei Zhang, Xiaofeng Huang, Xiaoming Zha, Jue Wang
Summary: The study compared the efficacy and safety of 2-weekly nanoparticle albumin-bound paclitaxel (nP) and 3-weekly docetaxel regimens as neoadjuvant systemic therapy for breast cancer. The nP group achieved higher pathological complete response rates, especially in patients with triple-negative tumor cells and high Ki67 levels. However, grades 3-4 peripheral sensory neuropathies were more frequent in the nP group.
Article
Oncology
Yuan Yuan, Jin Sun Lee, Susan E. Yost, Sierra Min Li, Paul H. Frankel, Christopher Ruel, Daniel Schmolze, Kim Robinson, Aileen Tang, Norma Martinez, Daphne Stewart, James Waisman, Laura Kruper, Veronica Jones, Andrea Menicucci, Sahra Uygun, Erin Yoder, Bastiaan van der Baan, John H. Yim, Christina Yeon, George Somlo, Joanne Mortimer
Summary: The combination of carboplatin and nab-paclitaxel showed manageable toxicity and encouraging antitumor activity in early stage high-risk triple-negative breast cancer. Immune-hot GSIS was associated with higher pCR rate and RCB class 0/1, providing rationale for future neoadjuvant trials in TNBC. Additional development of GSIS as a clinically applicable assay is indicated.
Article
Oncology
Julia Foldi, Andrea Silber, Emily Reisenbichler, Kamaljeet Singh, Neal Fischbach, Justin Persico, Kerin Adelson, Anamika Katoch, Nina Horowitz, Donald Lannin, Anees Chagpar, Tristen Park, Michal Marczyk, Courtney Frederick, Trisha Burrello, Eiman Ibrahim, Tao Qing, Yalai Bai, Kim Blenman, David L. Rimm, Lajos Pusztai
Summary: The Phase I/II trial aimed to evaluate the safety and efficacy of durvalumab in combination with other therapies for triple-negative breast cancer. The study found that the combination treatment resulted in a 44% pathologic complete response rate, with some patients experiencing grade 3/4 adverse events. Results suggest potential benefits of the combination therapy, particularly in patients with high stromal tumor-infiltrating lymphocytes.
Article
Biochemistry & Molecular Biology
Mahmoud Rayan, Seba Shadafny, Adam Falah, Mizied Falah, Saleh Abu-Lafi, Sare Asli, Anwar Rayan
Summary: A novel conjugate compound IDD-1010, composed of docetaxel and biotin, exhibits potent anti-cancer activity in in vitro and in vivo studies, showing increased apoptosis and mitotic arrest in prostate cancer cells. Toxicology studies indicate that IDD-1010 has a maximal tolerated dose of 150 mg/kg in mice and shows better efficacy in reducing tumor volume and weight compared to Paclitaxel. These findings suggest that IDD-1010 has potential as a new treatment option for prostate cancer with a wider therapeutic window.
Article
Oncology
Rui Wan, Yanrong Guo, Xuezhi Hao, Zhijie Wang, Jianchun Duan, Jie Wang
Summary: This study retrospectively analyzed the efficacy and safety of nab-paclitaxel monotherapy and combined nab-paclitaxel and immune checkpoint inhibitors (ICIs) in relapsed small-cell lung cancer (SCLC) patients. The results showed a numerically higher objective response rate in the combined treatment group, but no survival superiority compared to monotherapy was observed. The safety profiles of both groups were tolerable.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Review
Oncology
Youwen Chen, Rui Liu, Chenxi Li, Yurong Song, Guangzhi Liu, Qingcai Huang, Liuchunyang Yu, Dongjie Zhu, Cheng Lu, Aiping Lu, Linfu Li, Yuanyan Liu
Summary: Nab-paclitaxel improves water solubility and safety, inhibits microtubule depolymerization for anti-cancer effects, easily taken up by tumor and immune cells, and exhibits significant immunostimulatory activities to promote cancer-immunity cycle.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Review
Oncology
Elizabeth R. Smith, Marilyn Huang, Matthew P. Schlumbrecht, Sophia H. L. George, Xiang-Xi Xu
Summary: Taxanes and CDK4/6 inhibitors are effective antimitotic drugs used in the treatment of solid tumors. Combining paclitaxel with CDK4/6 inhibitors shows potential as a therapeutic option for recurrent ovarian cancer.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Christopher G. C. A. Jackson, Tak Hung, Eva Segelov, Paula Barlow, Hans Prenen, Blair McLaren, Noelyn Anne Hung, Katriona Clarke, Tsu-Yi Chao, Ming-Shen Dai, Hsien-Tang Yeh, David L. Cutler, Douglas Kramer, Jimmy He, Jay Zhi, Wing-Kai Chan, Rudolf Kwan, Sanjeev Deva
Summary: This study demonstrated that oral administration of paclitaxel with encequidar achieved comparable AUC to intravenous administration, with good tolerability and the potential to be an alternative to IV administration.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2021)
Article
Oncology
Sayeh M. Lavasani, George Somlo, Susan E. Yost, Paul H. Frankel, Christopher Ruel, Yujie Cui, Mireya Murga, Aileen Tang, Norma Martinez, Laura Kruper, Lusine Tumyan, Daniel Schmolze, Christina Yeon, Yuan Yuan, James R. Waisman, Joanne Mortimer
Summary: This study evaluated the safety and efficacy of nab-paclitaxel, trastuzumab, and pertuzumab as neoadjuvant therapy in patients with HER2+ breast cancer. The results showed a pCR rate of 64% and fewer treatment-associated toxicities, suggesting the possibility of avoiding anthracyclines and carboplatin in this patient population.
Review
Oncology
Ilenia Migliaccio, Martina Bonechi, Amelia McCartney, Cristina Guarducci, Matteo Benelli, Laura Biganzoli, Angelo Di Leo, Luca Malorni
Summary: CDK4/6 inhibitors in combination with endocrine therapy are the main treatment for metastatic breast cancer, but resistance can lead to treatment failure. Current approaches for patients who progress on CDK4/6 inhibitors include endocrine therapy alone, combination therapy, or chemotherapy. New agents are being developed based on potential mechanisms of acquired resistance.
CANCER TREATMENT REVIEWS
(2021)
Review
Biochemistry & Molecular Biology
Alessia Vignoli, Emanuela Risi, Amelia McCartney, Ilenia Migliaccio, Erica Moretti, Luca Malorni, Claudio Luchinat, Laura Biganzoli, Leonardo Tenori
Summary: Precision oncology focuses on selecting the optimal therapy for individual patients with breast cancer, who need appropriate stratification for maximizing survival and quality of life. Gene-expression tools assist in estimating risk and benefit from chemotherapy, while NMR metabolomics has shown promising results in BC research.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Oncology
Laura Biganzoli, Nicole Matteo Luca Battisti, Hans Wildiers, Amelia McCartney, Giuseppe Colloca, Ian H. Kunkler, Maria-Joao Cardoso, Kwok-Leung Cheung, Nienke Aafke de Glas, Rubina M. Trimboli, Beatriz Korc-Grodzicki, Enrique Soto-Perez-de-Celis, Antonio Ponti, Janice Tsang, Lorenza Marotti, Karen Benn, Matti S. Aapro, Etienne G. C. Brain
Summary: Breast cancer in older adults is becoming more common and challenging to manage due to its heterogeneity and lack of specific evidence. An expert taskforce expanded and updated guidelines with endorsement from the European Cancer Organisation, including factors like chemotherapy toxicity prediction, cultural and social considerations, and genetic screening. Age should not be the sole factor in decision-making, with careful consideration of geriatric assessments, life expectancy, and patient preferences.
Article
Oncology
Samantha Di Donato, Alessia Vignoli, Chiara Biagioni, Luca Malorni, Elena Mori, Leonardo Tenori, Vanessa Calamai, Annamaria Parnofiello, Giulia Di Pierro, Ilenia Migliaccio, Stefano Cantafio, Maddalena Baraghini, Giuseppe Mottino, Dimitri Becheri, Francesca Del Monte, Elisangela Miceli, Amelia McCartney, Angelo Di Leo, Claudio Luchinat, Laura Biganzoli
Summary: Metabolomics has the potential to improve risk stratification in elderly patients with eCRC by identifying patients with residual micrometastases after surgery. The serum metabolomic fingerprints efficiently discriminated patients with relapse-free eCRC from those with metastatic disease, correctly predicting relapse in 69% of relapsed eCRC patients. The metabolomic score was strongly associated with prognosis independently of tumor stage.
Article
Chemistry, Multidisciplinary
Alessia Vignoli, Elena Mori, Samantha Di Donato, Luca Malorni, Chiara Biagioni, Matteo Benelli, Vanessa Calamai, Stefano Cantafio, Annamaria Parnofiello, Maddalena Baraghini, Alessia Garzi, Francesca Del Monte, Dario Romagnoli, Ilenia Migliaccio, Claudio Luchinat, Leonardo Tenori, Laura Biganzoli
Summary: The study investigated the changes in preoperative and postoperative serum metabolomic fingerprints of CRC patients and found that some metabolic changes may be associated with cancer relapse. Certain metabolites such as pyruvate and HDL-related parameters appear to play important roles in discriminating between preoperative and postoperative serum samples of CRC patients.
APPLIED SCIENCES-BASEL
(2021)
Review
Oncology
Giampaolo Bianchini, Grazia Arpino, Laura Biganzoli, Sara Lonardi, Fabio Puglisi, Daniele Santini, Matteo Lambertini, Giovanni Pappagallo
Summary: This study discusses the effectiveness and side effects of antibody-drug conjugates (ADCs) in the treatment of solid tumors, with nausea and vomiting being the most common adverse reactions. The expert panels propose methods and recommendations for preventing and mitigating ADC-associated emesis, but further research and evidence are needed.
Article
Oncology
Ilenia Migliaccio, Marta Paoli, Emanuela Risi, Chiara Biagioni, Laura Biganzoli, Matteo Benelli, Luca Malorni
Summary: This study aims to investigate the prognostic value of PIK3CA mutations and copy number gain in hormone receptor-positive and HER2-negative breast cancer. Analysis of samples from three datasets revealed that 8-10% of patients had PIK3CA mutations and gain, which were associated with worse outcome. The clinical benefit of targeted treatment was found to be similar among patients with different mutation types.
Review
Oncology
Mattia Garutti, Gaia Griguolo, Andrea Botticelli, Giulia Buzzatti, Carmine De Angelis, Lorenzo Gerratana, Chiara Molinelli, Vincenzo Adamo, Giampaolo Bianchini, Laura Biganzoli, Giuseppe Curigliano, Michelino De Laurentiis, Alessandra Fabi, Antonio Frassoldati, Alessandra Gennari, Caterina Marchio, Francesco Perrone, Giuseppe Viale, Claudio Zamagni, Alberto Zambelli, Lucia Del Mastro, Sabino De Placido, Valentina Guarneri, Paolo Marchetti, Fabio Puglisi
Summary: Breast cancer is a leading cause of cancer-related morbidity and mortality in women worldwide, and estimating the risk of relapse for individual cases remains challenging. The IRIDE working group reviewed literature evidence to identify the relevant features predicting relapse in hormone receptor-positive/HER2-negative early breast cancer, aiming to provide guidance for clinicians in managing these cases effectively.
Article
Oncology
Federica Miglietta, Michela Cinquini, Maria Vittoria Dieci, Laura Cortesi, Carmen Criscitiello, Filippo Montemurro, Lucia Del Mastro, Alberto Zambelli, Laura Biganzoli, Alessia Levaggi, Chiara Delle Piane, Caterina Marchio, Massimo Calabrese, Lucio Fortunato, Pierfrancesco Franco, Bruno Meduri, Veronica Andrea Fittipaldo, Stefania Gori
Summary: This article provides clinical recommendations on the use of PARP inhibitors in the treatment of breast cancer patients with BRCA mutations. Based on the results of two clinical studies, the panel recommends the use of PARP inhibitors over single-agent chemotherapy in HR+/HER2- and triple-negative breast cancer, as PARP inhibitors have shown favorable outcomes in terms of PFS, ORR, and QoL.
Article
Oncology
Agnese Losurdo, Andrea Vittorio Emanuele Lisa, Mariano Tomatis, Antonio Ponti, Stefania Montemezzi, Elisabetta Bonzano, Lucio Fortunato
Summary: This study evaluates the performance of Italian Breast Centers during the COVID-19 pandemic compared to pre-pandemic times, and finds that there were no delays or changes in BC treatment in the Senonetwork partners, contradicting the globally reported decrease in performance of Italian Breast Centers.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Review
Oncology
Nicolo Matteo Luca Battisti, Nienke De Glas, Enrique Soto-Perez-de-Celis, Gabor Liposits, Michael Bringuier, Christine Walko, Stuart M. Lichtman, Matti Aapro, Kwok-Leung Cheung, Laura Biganzoli, Alistair Ring, Johanneke Portielje, Hans Wildiers, Etienne Brain
Summary: This study summarizes the evidence on efficacy, safety, and quality-of-life impacts of chemotherapy and the use and impact of gene expression profiling (GEP) in older patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer (EBC). The results show that chemotherapy survival benefits in older patients are unclear and GEP is less used. The prognostic role of GEP is established, but its predictive role remains unknown.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Biochemical Research Methods
Dario Romagnoli, Agostina Nardone, Francesca Galardi, Marta Paoli, Francesca De Luca, Chiara Biagioni, Gian Marco Franceschini, Marta Pestrin, Giuseppina Sanna, Erica Moretti, Francesca Demichelis, Ilenia Migliaccio, Laura Biganzoli, Luca Malorni, Matteo Benelli
Summary: DNA-methylation alterations are common in cancer and can be used as ideal markers for tumor quantification and classification. The computational framework MIMESIS utilizes minimal DNA-methylation signatures to accurately estimate tumor content and classify tumor type and molecular subtype in tissue and cell-free DNA samples. The study demonstrates the potential of MIMESIS in developing cost-effective and scalable DNA-methylation assays for precision oncology in clinical practice.
BRIEFINGS IN BIOINFORMATICS
(2023)
Article
Oncology
Peter van Dam, Mariano Tomatis, Antonio Ponti, Lorenza Marotti, Cynthia Aristei, Laura Biganzoli, Maria J. Cardoso, Kwok L. Cheung, Giuseppe Curigliano, Jakob De Vries, Donatella Santini, Francesco Sardanelli, Isabel Teresa Rubio
Summary: The study found that the quality of breast cancer care was well maintained in EUSOMA breast centers during the first wave of the COVID-19 pandemic, despite a decrease in the total number of new cases and a slightly higher tumor and lymph node stage at presentation.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Emanuela Risi, Camilla Lisanti, Alessia Vignoli, Chiara Biagioni, Agnese Paderi, Silvia Cappadona, Francesca Del Monte, Erica Moretti, Giuseppina Sanna, Luca Livraghi, Luca Malorni, Matteo Benelli, Fabio Puglisi, Claudio Luchinat, Leonardo Tenori, Laura Biganzoli
Summary: This study suggests that using proton nuclear magnetic resonance (1H NMR) spectroscopy to identify a metabolic signature can independently predict the risk of disease recurrence in elderly breast cancer (BC) patients, regardless of standard clinicopathological features.
TRANSLATIONAL ONCOLOGY
(2023)
Article
Oncology
Fatima Cardoso, Amelia McCartney, Antonio Ponti, Lorenza Marotti, Conny Vrieling, Alexandru Eniu, Berta Sousa, Carla Ripamonti, Luzia Travado, Sabine Spitz, Eva Jolly, Giuseppe Curigliano, Frederique Penault-Llorca, Frederic Lecouvet, Isabel T. Rubio, Laura Biganzoli
Summary: The European Society of Breast Cancer Specialists and the Advanced Breast Cancer Global Alliance have developed the first set of quality indicators for metastatic breast cancer (MBC) with the aim of ensuring high-quality care and adherence to guidelines in breast cancer centers.
EUROPEAN JOURNAL OF CANCER
(2023)